(Date:11/24/2008)...24 Leaders of Schering-P... update for investors on the company,s research pi...io that includes 46 new entities in clinical trial... studies. , , "Research and development is ...we continue our transformation," said Fred Hassan,...
(Date:11/24/2008)...nnovation leadership and long-term commitment to h.... 24 Schering-Plough Cor...update on boceprevir, its lead investigational ora...e III development. The company believes boceprevi...t-in-class protease inhibitor for treating chronic...
(Date:11/24/2008)...24 Schering-Plough Corpo...ant, its novel and selective adenosine2a receptor ... dose-finding trial in patients suffering from mod...otor fluctuations and abnormal involuntary movemen...d today at the company,s 2008 R&D Update meeti...
(Date:11/24/2008).... 24 GeneThera, Inc.,(P... offering its Real Time,PCR test for Johne,s dise... GeneThera is set to begin offering its Johne...2009. According to GeneThera Chairman, Dr. Tony M...al time PCR test for Johne,s disease,called Herd...
Breaking Medicine Technology:Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Covance Inc Invites You to Join the Webcast of Its 2009 Guidance Conference Call 30485 1USP wins CITAC award for paper on certified reference materials 30482 1Study identifies double balloon enteroscopy as cost effective approach for obscure GI bleeding 30479 1Study identifies double balloon enteroscopy as cost effective approach for obscure GI bleeding 30479 2Study identifies double balloon enteroscopy as cost effective approach for obscure GI bleeding 30479 3Study identifies double balloon enteroscopy as cost effective approach for obscure GI bleeding 30479 4Study identifies double balloon enteroscopy as cost effective approach for obscure GI bleeding 30479 5Availity Achieves 2008 eHealthcare Leadership Award 30476 1Availity Achieves 2008 eHealthcare Leadership Award 30476 2...cet on TMC125, an Investigational NNRTI,from Tibot...ta from two,ongoing Phase 3 studies (DUET-1 and DU...ts with documented non-nucleoside reverse,transcri...),resistance reached an undetectable viral load (d... 50 HIV-1 RNA copies/mL) with,TMC125 (etravirine),...
...6, 2007 /PRNewswire-FirstCall/ --,Genzyme Corp. an...Phase 3 clinical studies to assess the safety and ...non-antibiotic, polymer,therapy for patients with ...The second Phase 3 study of tolevamer liquid is fu...ear. , In this first Phase 3 study known as the Po...
Other Medicine Technology:TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4(Date:12/1/2008)...FirstCall/ -- The Ensign Group, Inc.,(Nasdaq: E...bilitation Center in,Pocatello, Idaho has success...,Medicaid Services, Special Focus program. , ...71213/LATH168LOGO ) , A clinical team led b...are,& Rehabilitation Center, completed the co...
(Date:12/1/2008)...e/ -- In the face of one of the most,severe econo...Health Board of,Directors has approved an investm... the Sutter Health Retirement Plan. Employee pensi...cks and bonds, have been among the biggest,casual...onservatively,invested, the Sutter Health Retirem...
(Date:12/1/2008)...ce of higher mortality and lower surgery rates in ...vere leakage may be related to the complexity of e...ding to findings of a Mayo Clinic study published ..., Mitral valve prolapse affects approximately 150...ac surgery, preferably valve repair rather than re...
(Date:12/1/2008)...iciaries for Par and Poker Celebrity Challenge for...e-USNewswire/ -- The Joyner-Walker Foundation toda...he Judeo Christian Health Clinic, Inc. as the Tamp...ty Challenge for Charity following a competitive a...iate that events like this give back to the host c...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2...private company and was set up in 1994 in London. ...t has accepted to provide health care facility// f... three-year contract. It would provide General Pra...y 3 doctors and 7 nurses. It has won a ?5m contrac...
... study by rheumatologists at the University of Sou...te diet doesn’t increase the bone loss// for adult...t loss and it was published in the online issue of...l. A more broadly used weight reducing technique...
...r 15,000 people in Indonesia are being killed by d... jointly by National Narcotics Agency BNN// and th...rably large amount of money was being spent on dru...ple in the country. 'Some Rupiah12 trillions (loca...
...hniques, the Chinese Tai chi and various relaxatio...are programme held here on May 28 by the Rajayoga ...cted by Dr Girish Patel, secretary of the Medical ...rofession, the programme will deal with finding so...
Other Medicine News:Health News:Low Carbohydrate Diet Packs No Bone Loss 2Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: